


Oral GLP-1 Agonists:


The Game-Changer in Obesity and Diabetes Therapy





What if managing diabetes or obesity could be as simple as swallowing a pill each morning?

Oral GLP-1 treatments mark a major leap in diabetes and obesity care, condensing decades of research into daily pills. Early breakthroughs proved the concept—now next-gen molecules are closing the gap with injectable standards.

Decades of Discovery: The Evolution of GLP-1 Therapies



Today's Breakthroughs, Tomorrow's Promise

Current Only Approved Oral Agent	Next-Gen Oral Agents: Progress in the Pipeline
<p>Rybelsus® (oral semaglutide)</p> <ul style="list-style-type: none">Approved in 2019 for type 2 diabetes—once-daily tabletDelivers 1–1.4% A1c reduction and modest weight lossSOUL trial: ~14% reduction in major cardiovascular events	<ul style="list-style-type: none">Orforglipron (Eli Lilly): Phase 3, small molecule—~2.2% A1c drop, up to 15% weight loss at 72 weeksAmycretin (Novo Nordisk): Early trials—13%+ weight loss for orals, up to 24% subcutaneous <div></div>

While the pipeline shows incredible promise, the journey isn't without its hurdles—practical challenges still shape how far and fast oral GLP-1s can truly go.

Practical Challenges: What's Holding Back the Pill Promise?

- 01
Daily dosing (vs. weekly shots) may affect consistency
- 02
Some oral drugs require fasting—impacting convenience
- 03
Premium pricing and periodic shortages limit real-world access

Key Industry Players Redefining Diabetes Care



Semaglutide (Ozempic, Rybelsus) formulations & delivery



Orforglipron – small-molecule oral formulations




MET-097i – oral GLP-1 candidates



Mazdutide – competing in China

Understanding the Regional Patent Activities Around GLP-1s



Future Outlook



- Pipeline promises more oral agents with near-injectable performance
- Expanding uses: obesity, cardiovascular and kidney risk, and adjunct therapies
- Patent cliffs to spark generic and biosimilar launches, especially in emerging markets
- Regulatory and reimbursement trends will hinge on obesity and CV trial outcomes

Beyond Pills: Shaping the Future of Metabolic Health

Combine convenience, powerful outcomes, and new possibilities.

Partner with us in shaping the future of GLP-1 R&D and driving next-generation solutions for metabolic health.